The article can be viewed at https://www.frontiersin.org/articles/10.3389/fonc.2018.00114/full.

Cannabis Science’s latest article explores the potential of combination approaches employing CBDs with radiotherapy and smart biomaterials toward enhancing therapeutic efficacy during treatment of pancreatic and lung cancers. The significance of these research findings, considerations for further research, and a viable roadmap to clinical translation are discussed in this article.

“This second publication reflects our ongoing work and we continue to examine the effect of CBDs with and without radiation therapy on lung and pancreatic cancer. This work will form part of our applications to the U.S. Food and Drug Administration (FDA). As we continue this work we will expand our pharmaceutical development program from farm to bedside,” stated Dr. Allen A. Herman, Cannabis Science’s Chief Medical Officer (CMO).

The innovative drug delivery strategy for CBDs is consistent with the three primary elements in Cannabis Science’s drug development program: (1) Defining the effectiveness and specificity of CBDs being tested; (2) Identifying and testing drug delivery mechanisms; and (3) Testing and evaluating the impact of co-interventions, and the application of additional diagnostic and/or therapeutic procedures to participants in randomized controlled trials. The Company’s initial results point to the importance of drug delivery systems and the impact of co-interventions.

The initial results of Cannabis Science’s current research were published in September 2017 in Frontiers in Oncology. This peer-reviewed article, “Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids”, has been viewed more than 11,000 times, and has more views than 96% of all Frontiers’ articles. The first article addresses drug delivery and highlights an innovative strategy to transport CBDs directly to cancer cells with minimal toxicities or side effects that have so far hampered clinical translation efforts.

Frontiers publishes several of the most-cited open-access journals in the world, and is one of the largest and fastest-growing open-access publishers with millions of monthly page views. Compared to all journals (subscription and open-access), Frontiers’ journals rank 1stmost cited in four categories, namely Neurosciences, Psychology, Multidisciplinary Psychology, and Plant Sciences.

To view Cannabis Science’s first article in Frontiers in Oncology:

https://www.frontiersin.org/articles/10.3389/fonc.2017.00208/full